Roth Capital Downgrades Exact Sciences (EXAS) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Jefferies Cuts Price Target on Exact Sciences (EXAS) Following Disappointing Outlook
February 25, 2016 9:29 AM ESTJefferies maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $13.00 (from $15.00), following the company's 4Q. . In light of the 4Q test volume shortfall, EXAS' initial outlook for flattish trends in 1Q16 was disappointing. EXAS reaffirmed its '16 revenue... More
Stephens Downgrades Exact Sciences (EXAS) to Equal Weight
February 25, 2016 7:55 AM ESTStephens downgraded Exact Sciences (NASDAQ: EXAS) from Overweight to Equal Weight.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $5.87 yesterday.
... MoreCraig-Hallum Downgrades Exact Sciences (EXAS) to Hold
February 24, 2016 1:37 PM ESTCraig-Hallum downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Hold.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $6.41 yesterday.
... MoreExact Sciences (EXAS) Tops Q4 EPS by 6c, Maintains Cologuard Outlook
February 24, 2016 7:31 AM ESTExact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.41), $0.06 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $14.82 million.
2016 Outlook
The company continues to anticipate completing more than 240,000 Cologuard tests during 2016, generating between... More
